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Results: Using the digital log, the data concerning the TLP 
can be stored in a structured way, rather than in open text 
parts of a patient’s dossier. The action codes regarding the 
anatomical changes that are present in the log showed a 
clear overview of possible variations during treatment. The 
RTTs scored an average of 7.8/10 in the questionnaire on the 
digital log overview. In succession, this overview showed a 
clear course of action regarding these anatomical changes 
using the TLP. 
 
Conclusion: The implementation and use of a digital log 
improves the overview of the anatomical changes observed 
on CBCT during radiotherapy. Moreover, the data gathered 
within the log can retrospectively be used for clinical or 
research questions regarding clinical IGRT decisions for a 
specific target area. 
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Purpose or Objective: Vestibular schwannomas (acoustic 
neuromas) are common benign tumors that arise from the 
Schwann cells of the vestibular nerve. Management options 
include observation with neuroradiological follow-up, 
microsurgical resection or stereotactic radiotherapy (SRS). 
The aim of the study was to evaluate tumor size and 
treatment tolerance of patients treated with CyberKnife (CK) 
radiosurgery for vestibular schwannoma (VS). 
 
Material and Methods: Between 2011 and 2014, 96 patients 
with 100 vestibular schwannomas were treated with SRS using 
CK. The vestibular schwannomas of 5 patients were 
associated with type II neurofibromatosis. Twenty patients 
were operated on before radiosurgery. All patients had more 
than one year follow-up. The median age at the time of 
treatment was 59 ( range 21-88 years). Median tumor 
diameter was 18 mm (range 3-48 mm) and the median 
prescribed dose was 16 Gy (12-21 Gy). In 29 patients, single 
dose of 12-18 Gy was delivered, in 31 total dose of 12-16 Gy 
was delivered with two fractions and the remaining 40 
patients were treated with 15-21 Gy delivered in 3 fractions 
baseline. Hearing was classified according to the Gardner 
Robertson grading scale (48% of patients had serviceable 
hearing).  
 
Results: At 12 month after SRS we observed that :15% of 
tumors slightly expanded, in 8% patients slight expansion of 
tumor followed by regression, 11% of tumors increased in 
size, but then remained stable, 58% were stable in size and 
8% responded to therapy. Overall, tumor swelling was, thus, 
observed in 34% of patients. At first year no patient required 
neurosurgical intervention due to tumor progression or 
brainstem compression symptoms. 77% patients had stable 
level of hearing after SRS, 9% declared improvement and 14% 
worsening of hearing. The rate of complications was very 
low, with most consisting of a transient worsening of 
preexisting symptoms. At the last assessment, full facial and 
trigeminal nerve function was preserved in 95% and 98% of 
patients, respectively; the only facial deficit (House-
Brackmann grade III) occurred in patient who received a 
single dose of 18 Gy in one fraction early in our experience, 
the remaining were mild, grade II dysfunctions. None of the 
patients treated with doses lower than 13 Gy experienced 
facial or trigeminal neuropathy. 
 
Conclusion: Cyber Knife radiosurgery is a safe and effective 
treatment for VS characterized by high probability of 
retaining functional hearing and facial and trigeminal nerve 
function preservation. In about one third of patients a tumor 
swelling after treatment is observed but reliable tumor 
control and persistence of neural dysfunctions assessment 
requires longer follow-up. 
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Purpose or Objective: Soft tissue sarcomas are rare 
malignancies, commonly arising in limbs, with an annual 
incidence of 3,298 cases in the UK in 2010. Their rarity leads 
to a lack of published data and experience in limb 
immobilisation for radiotherapy planning. The IMRiS trial is a 
phase II study of intensity modulated radiotherapy (IMRT) in 
primary bone and soft tissue sarcoma, due to open in late 
2015. As part of a pre-trial quality assurance (PT QA) 
programme, we report on the current UK practice of limb 
soft tissue sarcoma (LSTS) immobilization and the 
significance for multi-centre trial recruitment. 
 
Material and Methods: A facility questionnaire (FQ) was 
circulated to 29 IMRiS centres to investigate variation in 
immobilisation devices (ID), planning techniques, and imaging 
protocols. A workshop was held to address limb sarcoma 
immobilisation and patient set up. Robustness of patient 
setup at each centre was evaluated based on setup audits, 
frequency of imaging and the number of patients (pts) 
treated per centre per annum. 
 
Results: 27 questionnaires were returned. Less than 1/3 of 
the responders routinely treat their pts with IMRT (8/27). The 
remaining 2/3 have little or no experience with IMRT for 
LSTS. Vacuum bags are currently the most popular ID (9/27), 
followed by thermoplastic shells (7/27), limb boards (5/27), 
other devices (3/27) of which 2 used in-house developed and 
customisable devices, and 1 used common positioning pads. 2 
centres combined the use of vacuum bag and shell. 9 centres 
had audited their setup. However, only 4 had calculated their 
setup margins on the basis of systematic and random error. 
The majority of centres follow the recommendations to 
perform imaging on days 1 to 5 and then weekly. 6 centres 
perform daily imaging (all 6 treat LSTS with IMRT). Of 6 
centres with a high level of setup robustness, 3 are IMRT 
centres. On average centres treat 24 pts annually (range 3-
53). Currently over half the centres treat less than the 
calculated average number of pts. 
 
Conclusion: The results from the FQ and workshop 
demonstrate variations in treatment modality, ID and imaging 
frequency across the UK. 70% of IMRiS participating centres 
will be implementing or further developing IMRT in order to 
treat LSTS in the study. This will require a change in 
treatment modality (from 3DCRT to IMRT) in 9 centres. 
Comprehensive PT QA is required to ensure quality in a trial 
to be run at centres with such different levels of experience. 
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Robustness of patient setup is important to decrease 
variability arising from different ID. The PT QA program will 
encourage centres to assess robustness of setup through audit 
and calculation of centre specific margins. The majority of 
centres will need to review treatment verification as daily 
imaging is mandated for the trial. We anticipate that centres 
with less robust setup systems may need more support to 
safely implement IMRiS, and in response to this a discussion 
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Purpose or Objective: To quantify residual interfraction 
error after two-dimensional (2D) orthogonal kV set-up 
correction using cone-beam CT (CBCT) and 6DOF robotic 
couch for target localization in patients undergoing 
stereotactic radiotherapy. 
 
Material and Methods: After clinical setup using in-room 
lasers and skin/cradle marks placed at simulation, patients 
were imaged and repositioned according to orthogonal kV 
registration of bony landmarks to digitally reconstructed 
radiographs from the planning CT. A subsequent CBCT was 
matched to the planning CT using also soft tissue information 
and the resultant residual error was measured and corrected 
before treatment. Absolute averages, statistical means, 
standard deviations, and root mean square (RMS) values of 
observed error were calculated. 
 
Results: From June 2014 to October 2015 a total of 45 
patients with intracranial (15 pts), intrathoracic (19 pts) and 
abdominal (11 pts) lesions received 139 fractions of SBRT. 2D 
kV images revealed a vector mean setup deviations of 0,9 
mm (RMS). Table 1 shows residual translational shifts 
observed with CBCT. Means of pitch, roll and yaw errors were 
0,18° , 0,27° and 0,05°, respectively. Pitch, roll, and yaw 
errors were lower than 1° in 92%, 88% and 82% of images, 
respectively. According to tumor site, residual setup 
deviations seemed to be higher for abdominal lesions (RMS 
1,4 mm) compared with intrathoracic (RMS 1,1 mm) and 
intracranial lesions (RMS 1,0 mm). 
 
 
Conclusion: These data confirm the importance of CBCT to 
reduce interfraction errors, expecially when high dose per 
fraction is delivered. Residual interfraction shifts for 
intracranial lesions is lower than for other tumor sites, 
probably as consequence of poor relevance of organ motion 
in this site. 
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Purpose or Objective: Many studies have been conducted 
regarding the dosimetric advantages of prone positioning 
systems for breast radiotherapy treatments, especially for 
pendulous breasts. However, there is a shortage of 
publications considering the reproducibility of such systems. 
This study performs a retrospective patient set-up analysis of 
a prone positioning system. An estimation of the required 
safety margin was also calculated in an attempt to predict if 
patients undergoing breast irradiation in prone position could 
be safely treated without an online correction protocol. 
 
Material and Methods: A group of 21 patients with localized 
breast cancer were treated in prone position (New Horizon™ 
Prone Breastboard, CIVCO Medical Solutions) with a 
fractionation scheme of 3.2 Gy x 15 to the boost and 
simultaneously 2.7 Gy x 15 to the whole breast. An online 
correction protocol based on CBCT imaging was applied and 
the initial set-up deviations (i.e. the first registration data 
for each fraction) were used in this study. The overall mean 
population error (μ) for each translational direction was 
calculated, as well as the population systematic (Σ) and 
random (σ) components. These outcomes were subsequently 
compared to the results derived from an equally numbered 
group of patients treated in supine position (C-QUAL™ 
Breastboard, CIVCO Medical Solutions) with the same 
fractionation scheme. 
In both treatment positioning systems CBCT matching criteria 
was prioritized according to: 1 - Breast contour; 2 - Boost 
position; 3 - Chest wall. 
